Boston Planning and Development Agency

Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI

Dana-Farber’s Breast Oncology Center shared a post on X:

“We are leading a phase 2 study, called TRUDI, to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn if the intervention works in stage III, HER2-expressing Inflammatory Breast Cancer.”

Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI

Read further.

More featuring Dana-Farber’s Breast Oncology Center.

cancer Dana-Farber’s Breast Oncology Center Durvalumab inflammatory breast cancer OncoDaily Oncology Trastuzumab deruxtecan TRUDI